Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.

Wabe NT, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee AT, Spargo LD, Metcalf RG, Hall C, Proudman SM, Wiese MD.

J Rheumatol. 2016 Jul 15. pii: jrheum.151392. [Epub ahead of print]

PMID:
27422892
2.

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.

Sorich MJ, Rowland A, Kichenadasse G, Woodman RJ, Mangoni AA.

Br J Cancer. 2016 Jun 14;114(12):1313-7. doi: 10.1038/bjc.2016.147. Epub 2016 May 26.

PMID:
27228299
3.

Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?

Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Hall C, Spargo L, Metcalf R, Proudman SM, Wiese MD.

Int J Clin Pract. 2016 Apr;70(4):340-50. doi: 10.1111/ijcp.12785. Epub 2016 Mar 14.

PMID:
26987888
4.

Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia.

Hopkins AM, Proudman SM, Vitry AI, Sorich MJ, Cleland LG, Wiese MD.

Med J Aust. 2016 Feb 1;204(2):64-8.

PMID:
26821102
5.

Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ.

Eur J Cancer. 2016 Mar;55:122-30. doi: 10.1016/j.ejca.2015.11.025. Epub 2016 Jan 23. Review.

PMID:
26812186
6.

Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.

Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Spargo L, Metcalf R, Hall C, Proudman SM, Wiese MD.

Int J Rheum Dis. 2015 Dec 22. doi: 10.1111/1756-185X.12816. [Epub ahead of print]

PMID:
26692459
7.

Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.

Sorich MJ, Kichenadasse G, Rowland A, Woodman RJ, Mangoni AA.

Int J Cancer. 2016 May 1;138(9):2293-9. doi: 10.1002/ijc.29972. Epub 2016 Jan 6.

PMID:
26685869
8.

Pharmacists in Australian general practice: an opportunity for expertise in precision medicine.

Polasek TM, Rowland A, Wiese MD, Sorich MJ.

Ther Adv Drug Saf. 2015 Oct;6(5):186-8. doi: 10.1177/2042098615599947. No abstract available.

9.

Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ.

Br J Cancer. 2015 Dec 1;113(11):1635. doi: 10.1038/bjc.2015.325. Epub 2015 Sep 10. No abstract available.

10.

In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism.

Korprasertthaworn P, Polasek TM, Sorich MJ, McLachlan AJ, Miners JO, Tucker GT, Rowland A.

Drug Metab Dispos. 2015 Nov;43(11):1806-14. doi: 10.1124/dmd.115.064790. Epub 2015 Sep 1.

PMID:
26329789
11.

Targeted arginine metabolomics: A rapid, simple UPLC-QToF-MS(E) based approach for assessing the involvement of arginine metabolism in human disease.

van Dyk M, Mangoni AA, McEvoy M, Attia JR, Sorich MJ, Rowland A.

Clin Chim Acta. 2015 Jul 20;447:59-65. doi: 10.1016/j.cca.2015.05.014. Epub 2015 May 28.

PMID:
26026257
12.

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ.

Br J Cancer. 2015 Jun 9;112(12):1888-94. doi: 10.1038/bjc.2015.173. Epub 2015 May 19. Review.

13.

Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years.

Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Spargo L, Metcalf RG, Hall C, Proudman SM, Wiese MD.

Arthritis Res Ther. 2015 Mar 8;17:48. doi: 10.1186/s13075-015-0562-0.

14.

The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies--a systematic review.

Mohamed HJ, Sorich MJ, Kowalski SM, McKinnon R, Proudman SM, Cleland L, Wiese MD.

Eur J Clin Pharmacol. 2015 Apr;71(4):411-23. doi: 10.1007/s00228-015-1819-x. Epub 2015 Feb 18. Review.

PMID:
25687918
15.

CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.

Sorich MJ, Rowland A, McKinnon RA, Wiese MD.

Circ Cardiovasc Genet. 2014 Dec;7(6):895-902. doi: 10.1161/CIRCGENETICS.114.000669. Epub 2014 Sep 25.

16.

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS.

Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Epub 2014 Aug 12. Review.

17.

Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes.

Sorich MJ, Rowland A, Wiese MD.

Ther Adv Drug Saf. 2014 Apr;5(2):62-6. doi: 10.1177/2042098613520030. No abstract available.

18.

Cost-effectiveness of genotyping to guide treatment.

Sorich MJ, Wiese MD, Pekarsky B.

Pharmacogenomics. 2014 Apr;15(6):727-9. doi: 10.2217/pgs.14.24. No abstract available.

PMID:
24897279
19.

Gastrointestinal microbiota and metabolite biomarkers in children with autism spectrum disorders.

Wang L, Conlon MA, Christophersen CT, Sorich MJ, Angley MT.

Biomark Med. 2014;8(3):331-44. doi: 10.2217/bmm.14.12. Review.

PMID:
24712423
20.

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.

Dias MM, Pignon JP, Karapetis CS, Boige V, Glimelius B, Kweekel DM, Lara PN, Laurent-Puig P, Martinez-Balibrea E, Páez D, Punt CJ, Redman MW, Toffoli G, Wadelius M, McKinnon RA, Sorich MJ.

Pharmacogenomics J. 2014 Oct;14(5):424-31. doi: 10.1038/tpj.2014.16. Epub 2014 Apr 8.

PMID:
24709690
Items per page

Supplemental Content

Loading ...
Write to the Help Desk